BG107802A - Хуманизирани анти-lt-бета-r-антитела - Google Patents
Хуманизирани анти-lt-бета-r-антитела Download PDFInfo
- Publication number
- BG107802A BG107802A BG107802A BG10780203A BG107802A BG 107802 A BG107802 A BG 107802A BG 107802 A BG107802 A BG 107802A BG 10780203 A BG10780203 A BG 10780203A BG 107802 A BG107802 A BG 107802A
- Authority
- BG
- Bulgaria
- Prior art keywords
- antibody
- seq
- amino acid
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24028500P | 2000-10-13 | 2000-10-13 | |
US27528901P | 2001-03-13 | 2001-03-13 | |
US29998701P | 2001-06-21 | 2001-06-21 | |
PCT/US2001/032140 WO2002030986A2 (fr) | 2000-10-13 | 2001-10-12 | ANTICORPS HUMANISES ANTI-LT-β-R |
Publications (1)
Publication Number | Publication Date |
---|---|
BG107802A true BG107802A (bg) | 2004-01-30 |
Family
ID=27399340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG107802A BG107802A (bg) | 2000-10-13 | 2003-05-12 | Хуманизирани анти-lt-бета-r-антитела |
Country Status (25)
Country | Link |
---|---|
US (2) | US7429644B2 (fr) |
EP (1) | EP1326897A2 (fr) |
JP (1) | JP2004532608A (fr) |
KR (1) | KR20030041164A (fr) |
CN (1) | CN1547590A (fr) |
AR (1) | AR035352A1 (fr) |
AU (2) | AU1174702A (fr) |
BG (1) | BG107802A (fr) |
BR (1) | BR0114646A (fr) |
CA (1) | CA2425809A1 (fr) |
CZ (1) | CZ20031307A3 (fr) |
EA (1) | EA006945B1 (fr) |
EE (1) | EE200300179A (fr) |
GE (1) | GEP20063752B (fr) |
HU (1) | HUP0302573A2 (fr) |
IL (1) | IL155340A0 (fr) |
IS (1) | IS6779A (fr) |
MX (1) | MXPA03003144A (fr) |
NO (1) | NO20031642L (fr) |
NZ (1) | NZ525793A (fr) |
PL (1) | PL366307A1 (fr) |
SK (1) | SK5672003A3 (fr) |
TR (2) | TR200300478T2 (fr) |
WO (1) | WO2002030986A2 (fr) |
YU (1) | YU28503A (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
TW200416044A (en) * | 2002-07-01 | 2004-09-01 | Biogen Inc | Humanized anti-lymphotoxin β receptor antibodies |
EP1583503A4 (fr) * | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques |
AU2003303339A1 (en) * | 2002-12-20 | 2004-07-22 | Biogen Idec Ma Inc. | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
WO2005000898A2 (fr) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Purification et synthese preferentielle de molecules de liaison |
CA2545603A1 (fr) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees |
AU2005227322A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
US8153123B2 (en) * | 2004-12-09 | 2012-04-10 | La Jolla Institute For Allergy And Immunology | Method for restoring dendritic cell populations |
WO2006074399A2 (fr) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Molecules de liaison multispecifiques comprenant des peptides de connexion |
WO2007056227A2 (fr) | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Utilisation d'inhibiteurs de la voie du complément pour traiter des maladies oculaires |
JP2007295524A (ja) * | 2006-03-28 | 2007-11-08 | Denso Corp | 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム |
BRPI0711908B8 (pt) * | 2006-05-25 | 2021-05-25 | Glaxo Group Ltd | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. |
US20120282245A1 (en) | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
RU2486201C2 (ru) * | 2006-10-12 | 2013-06-27 | Дженентек, Инк. | Антитела к лимфотоксину-альфа |
US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
KR20090071652A (ko) * | 2006-10-20 | 2009-07-01 | 바이오겐 아이덱 엠에이 인코포레이티드 | 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료 |
EP2097455B1 (fr) | 2006-11-02 | 2014-10-22 | Genentech, Inc. | Anticorps anti facteur-d humanisés et leurs utilisations |
US8003761B2 (en) * | 2007-01-23 | 2011-08-23 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
CN101849001B (zh) | 2007-06-25 | 2014-07-16 | 艾斯巴技术-诺华有限责任公司 | 修饰抗体的方法和具有改善的功能性质的修饰抗体 |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
EP2710042A2 (fr) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
KR20160042438A (ko) | 2013-08-12 | 2016-04-19 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
US10179821B2 (en) | 2014-05-01 | 2019-01-15 | Genentech, Inc. | Anti-factor D antibodies |
ES2749383T3 (es) | 2014-11-06 | 2020-03-20 | Hoffmann La Roche | Variantes de la región Fc con unión al FcRn modificada y procedimientos de uso |
IL310460A (en) | 2015-07-14 | 2024-03-01 | Immunext Inc | Anti-CD154 antibody with improved binding, functional and safety characteristics |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
WO2017075173A2 (fr) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anticorps et conjugués anti-facteur d |
US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
KR20220130687A (ko) | 2019-12-11 | 2022-09-27 | 시락 게엠베하 인터내셔날 | Ltbr 및 edb 결합 도메인을 포함하는 다중특이성 결합 분자 및 이의 용도 |
WO2022117572A2 (fr) | 2020-12-02 | 2022-06-09 | Oncurious Nv | Agoniste de ltbr utilisé pour la polythérapie contre le cancer |
WO2022117569A1 (fr) | 2020-12-02 | 2022-06-09 | Oncurious Nv | Anticorps antagoniste de ccr8 en combinaison avec un anticorps agoniste du récepteur bêta de la lymphotoxine en thérapie contre le cancer |
CR20240246A (es) | 2021-12-20 | 2024-07-19 | F Hoffmann La Roche Ag | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
WO2023198848A1 (fr) | 2022-04-13 | 2023-10-19 | Vib Vzw | Agoniste de ltbr utilisé en polythérapie contre le cancer |
WO2023218320A1 (fr) * | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anticorps anti-récepteur de la lymphotoxine bêta et leurs procédés d'utilisation |
WO2024211478A1 (fr) | 2023-04-07 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement du cancer avec un agoniste du récepteur bêta de la lymphotoxine |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69132629T2 (de) | 1990-06-27 | 2002-04-18 | Biogen, Inc. | Oberflächenkomplexbildung von lymphotoxin |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (fr) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
EP0672143B1 (fr) | 1992-12-04 | 2008-06-04 | Biogen Idec MA Inc. | Lymphotoxine-beta, complexes de lymphotoxines-beta, preparations pharmaceutiques et leurs utilisations therapeutiques |
US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
CA2211443A1 (fr) * | 1995-01-26 | 1996-08-01 | Biogen, Inc. | Complexes de lymphotoxine-.alpha./.beta. et anticorps de recepteur anti-lymphotoxine-beta utiles en tant qu'agents anti-tumoraux |
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
PT1051187E (pt) | 1998-01-30 | 2004-03-31 | Biogen Inc | Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt) |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
TW200416044A (en) | 2002-07-01 | 2004-09-01 | Biogen Inc | Humanized anti-lymphotoxin β receptor antibodies |
EP1583503A4 (fr) | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques |
AU2003303339A1 (en) | 2002-12-20 | 2004-07-22 | Biogen Idec Ma Inc. | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
-
2001
- 2001-10-12 CN CNA018205917A patent/CN1547590A/zh active Pending
- 2001-10-12 JP JP2002534371A patent/JP2004532608A/ja not_active Withdrawn
- 2001-10-12 AU AU1174702A patent/AU1174702A/xx active Pending
- 2001-10-12 IL IL15534001A patent/IL155340A0/xx unknown
- 2001-10-12 TR TR2003/00478T patent/TR200300478T2/xx unknown
- 2001-10-12 WO PCT/US2001/032140 patent/WO2002030986A2/fr active Application Filing
- 2001-10-12 NZ NZ525793A patent/NZ525793A/en unknown
- 2001-10-12 EP EP01979824A patent/EP1326897A2/fr not_active Withdrawn
- 2001-10-12 BR BRPI0114646-7A patent/BR0114646A/pt not_active IP Right Cessation
- 2001-10-12 HU HU0302573A patent/HUP0302573A2/hu unknown
- 2001-10-12 SK SK567-2003A patent/SK5672003A3/sk not_active Application Discontinuation
- 2001-10-12 EA EA200300464A patent/EA006945B1/ru not_active IP Right Cessation
- 2001-10-12 GE GE5165A patent/GEP20063752B/en unknown
- 2001-10-12 CZ CZ20031307A patent/CZ20031307A3/cs unknown
- 2001-10-12 YU YU28503A patent/YU28503A/sh unknown
- 2001-10-12 EE EEP200300179A patent/EE200300179A/xx unknown
- 2001-10-12 PL PL01366307A patent/PL366307A1/xx not_active Application Discontinuation
- 2001-10-12 CA CA002425809A patent/CA2425809A1/fr not_active Abandoned
- 2001-10-12 AU AU2002211747A patent/AU2002211747B2/en not_active Expired - Fee Related
- 2001-10-12 AR ARP010104807A patent/AR035352A1/es not_active Application Discontinuation
- 2001-10-12 TR TR2006/02095T patent/TR200602095T2/xx unknown
- 2001-10-12 MX MXPA03003144A patent/MXPA03003144A/es not_active Application Discontinuation
- 2001-10-12 KR KR10-2003-7005232A patent/KR20030041164A/ko not_active Application Discontinuation
-
2003
- 2003-04-10 US US10/412,406 patent/US7429644B2/en not_active Expired - Fee Related
- 2003-04-10 NO NO20031642A patent/NO20031642L/no not_active Application Discontinuation
- 2003-04-11 IS IS6779A patent/IS6779A/is unknown
- 2003-05-12 BG BG107802A patent/BG107802A/bg unknown
-
2008
- 2008-06-30 US US12/165,276 patent/US20090092601A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IS6779A (is) | 2003-04-11 |
KR20030041164A (ko) | 2003-05-23 |
AR035352A1 (es) | 2004-05-12 |
WO2002030986A3 (fr) | 2003-03-13 |
NO20031642L (no) | 2003-06-13 |
EE200300179A (et) | 2003-08-15 |
AU2002211747B2 (en) | 2007-11-29 |
CZ20031307A3 (cs) | 2003-10-15 |
CA2425809A1 (fr) | 2002-04-18 |
EA200300464A1 (ru) | 2003-10-30 |
US7429644B2 (en) | 2008-09-30 |
IL155340A0 (en) | 2003-11-23 |
MXPA03003144A (es) | 2004-12-06 |
SK5672003A3 (en) | 2003-10-07 |
GEP20063752B (en) | 2006-02-27 |
WO2002030986A2 (fr) | 2002-04-18 |
TR200602095T2 (tr) | 2007-02-21 |
JP2004532608A (ja) | 2004-10-28 |
TR200300478T2 (tr) | 2004-10-21 |
NO20031642D0 (no) | 2003-04-10 |
PL366307A1 (en) | 2005-01-24 |
HUP0302573A2 (hu) | 2003-10-28 |
CN1547590A (zh) | 2004-11-17 |
AU1174702A (en) | 2002-04-22 |
US20090092601A1 (en) | 2009-04-09 |
NZ525793A (en) | 2008-04-30 |
US20040058394A1 (en) | 2004-03-25 |
BR0114646A (pt) | 2006-02-21 |
EA006945B1 (ru) | 2006-06-30 |
YU28503A (sh) | 2006-05-25 |
EP1326897A2 (fr) | 2003-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG107802A (bg) | Хуманизирани анти-lt-бета-r-антитела | |
AU2002211747A1 (en) | Humanized anti-LT-Beta-R antibodies | |
CN110914306B (zh) | 检查点抑制物双特异性抗体 | |
KR101754433B1 (ko) | 항-cd100 항체 및 이의 사용 방법 | |
KR102089114B1 (ko) | 항원 결합 단백질 및 암의 치료를 위한 어드레싱 산물로서 그의 용도 | |
US8901278B2 (en) | Pharmaceutical antibody compositions with resistance to soluble CEA | |
US11584801B2 (en) | Anti-5T4 antibodies and antibody-drug conjugates | |
AU2011321374B2 (en) | Novel anti-DR5 antibody | |
US7429645B2 (en) | Humanized anti-lymphotoxin beta receptor antibodies | |
JP2017506217A (ja) | 標的TGFβ阻害 | |
JP2024530368A (ja) | 抗体薬物複合体およびその用途 | |
WO2021244587A1 (fr) | Protéine de fusion anti-pd-l1/tgf-ss | |
RU2808632C2 (ru) | Виды комбинированной терапии рака, нацеливающиеся на cd38 и tgf-бета | |
ZA200303347B (en) | Humanized anti-LT-beta-R antibodies. | |
EA041266B1 (ru) | Биспецифические антитела-ингибиторы контрольной точки |